Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

Authors

Sandra M. Swain, Medstar Washington Hospital Center, Washington, DC
Sung-Bae Kim, University of Ulsan College of Medicine, Seoul, South Korea
Javier Cortes, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
Jungsil Ro, National Cancer Center, Goyang, South Korea
Vladimir Semiglazov, NN Petrov Research Institute of Oncology, St. Petersburg, Russia
Mario Campone, Centre René Gauducheau, Saint Herblain-Nantes, France
Eva Ciruelos, Medical Oncology Department, Madrid, Spain
Jean-Marc Ferrero, Centre Antoine Lacassagne, Nice, France
Andreas Schneeweiss, University Hospital, Heidelberg, Germany
Adam Knott, Roche Products, Welwyn, United Kingdom
Emma Clark, Roche Products, Welwyn, United KingdomFollow
Graham Ross, Roche Products, Welwyn, United Kingdom
Mark C. Benyunes, Genentech, South San Francisco, CA
Jose Baselga, Memorial Sloan-Kettering Cancer Center, Memorial Hospital

Document Type

Journal Article

Publication Date

5-2013

Journal

The Lancet Oncology

Volume

Volume 14, Issue 6

Inclusive Pages

461-471

Keywords

Antineoplastic Combined Chemotherapy Protocols--therapeutic use; Breast Neoplasms--drug therapy; Molecular Targeted Therapy--methods; Receptor; erbB-2--antagonists & inhibitors; Tumor Markers; Biological--antagonists & inhibitors

APA Citation

Swain, S. M., Kim, S. -., Cortés, J., Ro, J., Semiglazov, V., Campone, M., . . . Baselga, J. (2013). Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. The Lancet Oncology, 14(6), 461-471.

Peer Reviewed

1